Ivonescimab with chemoradiotherapy for nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new medicine called ivonescimab combined with the standard treatment (chemotherapy and radiation) for people with a high-risk type of nasopharyngeal cancer. It aims to see if this combination helps control the cancer better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a specific type of nasopharyngeal cancer (non-keratinizing) that is stage III (T3N2M0) and has not been treated before.
- You must be in good enough physical condition to be fully active or only limited in strenuous work (ECOG 0 or 1).
- Your blood counts, liver, kidney, thyroid, and heart function need to be within normal limits.
- You must not have certain infections like active hepatitis B or C, HIV, or active tuberculosis.
- You must not have an active autoimmune disease or have had certain lung conditions that required steroids in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ivonescimab, for people with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has come back or spread and no longer responds to standard treatments like chemotherapy and immunotherapy. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
This trial tests whether adding an immunotherapy drug called sintilimab to standard chemoradiotherapy (chemo and radiation) is better than chemoradiotherapy alone for a specific type of nasopharyngeal cancer that has spread to neck lymph nodes. Immunotherapy uses your own immune system to fight cancer, and the hope is that adding it before and after standard treatment can improve outcomes.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.